XNYS · Healthcare · Drug Manufacturers - General
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Q1 2026 | 6.85 | 8.55 | +24.82% | $19.80B | ✅ Beat | +0.35% | +4.32% | +18.23% |
| 2026-02-04 | Q4 2025 | 6.96 | 7.54 | +8.33% | $19.30B | ✅ Beat | +0.78% | -8.30% | -10.55% |
| 2025-10-30 |
| Q3 2025 |
| 5.96 |
| 7.02 |
| +17.79% |
| $17.60B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | 5.60 | 6.31 | +12.68% | $15.56B | ✅ Beat | — | — | — |
| 2025-05-01 | Q1 2025 | 3.02 | 3.34 | +10.60% | $12.73B | ✅ Beat | — | — | — |
| 2025-02-06 | Q4 2024 | 5.08 | 5.32 | +4.72% | $13.53B | ✅ Beat | — | — | — |
| 2024-10-30 | Q3 2024 | 1.45 | 1.18 | -18.62% | $11.44B | ❌ Miss | — | — | — |
| 2024-08-08 | Q2 2024 | 2.70 | 3.92 | +45.19% | $11.30B | ✅ Beat | — | — | — |
Showing last 8 quarters.